RxDoctor Payments Data

Latiaha Lewis, APRN

Psychiatric/Mental Health · East Hartford, CTNPI 1891411641

Payments from drug & device makers

$1,429in general payments, 2019–2025

Across 71 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$479
  • Neurocrine Biosciences, Inc.$267
  • AbbVie$158
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$138
  • Indivior Inc.$109
  • Takeda Pharmaceuticals U.S.A., Inc.$63
  • plus $213 from 6 others

What the payments were for

  • Food & beverage$1,429100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,429 in reported general payments places this provider in the 75th percentile of 679 psychiatric/mental health providers in Connecticut.

See all psychiatric/mental health providers in Connecticut

Medicare billing

Part B allowed, 2024
$16,117
Medicare patients
63
Services billed
180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl101$136,513
Invega SustennaPaliperidone Palmitate18$59,032
LybalviOlanzapine/Samidorphan Malate12$21,001
Aripiprazole53$11,600
TrintellixVortioxetine Hydrobromide47$7,931
Lurasidone Hcl26$3,951
Clozapine59$3,461
Paliperidone ErPaliperidone28$3,351
Quetiapine Fumarate ErQuetiapine Fumarate18$3,247
Fluphenazine Hcl50$3,027
Quetiapine Fumarate124$2,753
Divalproex Sodium39$2,406
Olanzapine48$1,940
Trazodone Hcl165$1,874
Hydroxyzine Hcl62$1,669

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$158$136,513101 claims
Johnson & JohnsonInvega Sustenna$21$59,03218 claims
Alkermes, Inc.Lybalvi$41$21,00112 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$63$7,93147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 679 psychiatric/mental health providers in Connecticut.

Other psychiatric/mental health in East Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →